Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis
-
November 4, 1988
-
Source: MMWR. Morbidity and mortality weekly report. 1988; 37(43):663-4, 669-75.
[PDF-335.30 KB]
Details:
-
Corporate Authors:
-
Description:Since 1979, when the last Immunization Practices Advisory Committee (ACIP) statement on vaccination with Bacillus of Calmette and Guerin (BCG*) was published, additional data have been published on the epidemiology of tuberculosis (TB) in the United States and on the efficacy of childhood BCG vaccines. As a result, ACIP and the Advisory Committee for Elimination of Tuberculosis have issued the following educational update on BCG vaccines.
Immunization with BCG vaccine lowers the risk of serious complications of primary TB in children (1-4). However, BCG vaccination should be considered only for children with negative tuberculin skin tests who fall into the following categories: 1) those who cannot be placed on isoniazid preventive therapy but who have continuous exposure to persons with active disease; 2) those with continuous exposure to patients with organisms resistant to isoniazid and rifampin; or 3) those belonging to groups with exceptionally high annual rates of new infection (i.e., greater than 1% per year).
BCG vaccination is no longer recommended for health-care workers or other adults at high risk for acquiring TB infection. In addition, BCG should not be given to persons who are immunocompromised, including those with human immunodeficiency virus (HIV) infection.
-
Subjects:
-
Source:
-
Pubmed ID:3141765
-
Document Type:
-
Place as Subject:
-
Volume:37
-
Issue:43
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
